Aviki, Emeline M.
Thom, Bridgette
Braxton, Kenya
Chi, Andrew J.
Manning-Geist, Beryl
Chino, Fumiko
Brown, Carol L.
Abu-Rustum, Nadeem R.
Gany, Francesca M.
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Article History
Received: 19 August 2021
Accepted: 10 November 2021
First Online: 25 November 2021
Declarations
:
: The MSKCC Institutional Review Board (IRB) determined the survey to be a quality improvement project and, as such, exempt from IRB approval.
: Not applicable.
: Not applicable.
: BT reports the following, outside the submitted work: an Immediate family member has stock and other ownership interests in Caladrius Biosciences, Mediwound, Sierra Oncology, Lipocine, Aduro Biotech, MEI Pharma, Oncternal Therapeutics, Avadel Pharmaceuticals, Chimerix, Avidity Biosciences, Sutro Biopharma, Adma Pharma, Concert Pharmaceuticals, Process Pharmaceuticals, Curis, IMV, Arcus Biosciences, Iovance Biotherapeutics, Qiagen, Revance Therapeutics, DermTech, Zimmer BioMet, Axonics Modulation Technologies, Halozyme, Mallinckrodt, Chinook Therapeutics, OncoSec, Stemline Therapeutics. NRA reports the following, outside the submitted work: grant from Stryker/Novadaq (paid to institution); grant from Olympus (paid to institution); grant from GRAIL (paid to institution). Memorial Sloan Kettering Cancer Center (MSK) has financial interests relative to GRAIL. As a result of these interests, MSK could ultimately potentially benefit financially from the outcomes of this research.